420 related articles for article (PubMed ID: 15379937)
21. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
22. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen.
Kimmick GG; Lovato J; McQuellon R; Robinson E; Muss HB
Breast J; 2006; 12(2):114-22. PubMed ID: 16509835
[TBL] [Abstract][Full Text] [Related]
23. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
Nishiyama T; Hashimoto Y; Takahashi K
Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
[TBL] [Abstract][Full Text] [Related]
24. Physiology and endocrinology of hot flashes in prostate cancer.
Engstrom CA; Kasper CE
Am J Mens Health; 2007 Mar; 1(1):8-17. PubMed ID: 19482779
[TBL] [Abstract][Full Text] [Related]
25. Quality of life in men treated with carbon ion therapy for prostate cancer.
Wakatsuki M; Tsuji H; Ishikawa H; Yanagi T; Kamada T; Nakano T; Suzuki H; Akakura K; Shimazaki J; Tsujii H
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1010-5. PubMed ID: 18495370
[TBL] [Abstract][Full Text] [Related]
26. Incidence and management of hot flashes in prostate cancer.
Spetz AC; Zetterlund EL; Varenhorst E; Hammar M
J Support Oncol; 2003; 1(4):263-6, 269-70, 272-3; discussion 267-8, 271-2. PubMed ID: 15334868
[TBL] [Abstract][Full Text] [Related]
27. Endocrine complications of androgen-deprivation therapy in men with prostate cancer.
Harle LK; Maggio M; Shahani S; Braga-Basaria M; Basaria S
Clin Adv Hematol Oncol; 2006 Sep; 4(9):687-96. PubMed ID: 17099626
[TBL] [Abstract][Full Text] [Related]
28. Androgen deprivation therapy for prostate cancer: effects on hand function.
Soyupek F; Soyupek S; Perk H; Ozorak A
Urol Oncol; 2008; 26(2):141-6. PubMed ID: 18312932
[TBL] [Abstract][Full Text] [Related]
29. Comparison of objective and patient-reported hot flash measures in men with prostate cancer.
Hanisch LJ; Palmer SC; Marcus SC; Hantsoo L; Vaughn DJ; Coyne JC
J Support Oncol; 2009; 7(4):131-5. PubMed ID: 19731578
[TBL] [Abstract][Full Text] [Related]
30. Complications of androgen deprivation therapy in prostate cancer.
Schwandt A; Garcia JA
Curr Opin Urol; 2009 May; 19(3):322-6. PubMed ID: 19318949
[TBL] [Abstract][Full Text] [Related]
31. Intermittent androgen ablation in patients with biochemical failure after pelvic radiotherapy for localized prostate cancer.
Cury FL; Souhami L; Rajan R; Tanguay S; Gagnon B; Duclos M; Shenouda G; Faria SL; David M; Freeman CR
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):842-8. PubMed ID: 16289909
[TBL] [Abstract][Full Text] [Related]
32. Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.
Nishiyama T; Suzuki K; Yamana K; Tonegawa E; Wako K; Takahashi K
Expert Rev Anticancer Ther; 2006 Feb; 6(2):259-68. PubMed ID: 16445378
[TBL] [Abstract][Full Text] [Related]
33. Intravenous nutrient therapy eliminated androgen deprivation therapy-induced hot flashes in two men with prostate cancer.
Massey P
J Soc Integr Oncol; 2006; 4(4):153-6. PubMed ID: 17022923
[TBL] [Abstract][Full Text] [Related]
34. Acupuncture for the alleviation of hot flashes in men treated with androgen ablation therapy.
Ashamalla H; Jiang ML; Guirguis A; Peluso F; Ashamalla M
Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1358-63. PubMed ID: 20605360
[TBL] [Abstract][Full Text] [Related]
35. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
[TBL] [Abstract][Full Text] [Related]
36. Auricular acupuncture: a novel treatment for vasomotor symptoms associated with luteinizing-hormone releasing hormone agonist treatment for prostate cancer.
Harding C; Harris A; Chadwick D
BJU Int; 2009 Jan; 103(2):186-90. PubMed ID: 18710455
[TBL] [Abstract][Full Text] [Related]
37. Andropause syndrome in men treated for metastatic prostate cancer: a qualitative study of the impact of symptoms.
Grunfeld EA; Halliday A; Martin P; Drudge-Coates L
Cancer Nurs; 2012; 35(1):63-9. PubMed ID: 21558849
[TBL] [Abstract][Full Text] [Related]
38. A randomized prospective trial evaluating testosterone, haemoglobin kinetics and quality of life, during and after 12 months of androgen deprivation after prostatectomy: results from the Postoperative Adjuvant Androgen Deprivation trial.
Black PC; Basen-Engquist K; Wang X; Swartz RJ; Eddings T; Matin SF; Swanson D; Wood CG; Pisters LL; Babaian RJ; Troncoso P; Pettaway CA
BJU Int; 2007 Jul; 100(1):63-9. PubMed ID: 17552954
[TBL] [Abstract][Full Text] [Related]
39. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
40. "Staging the aging" when considering androgen deprivation therapy for older men with prostate cancer.
Dale W
J Clin Oncol; 2009 Jul; 27(21):3420-2. PubMed ID: 19506150
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
